2026 Volume 49 Issue 2 Pages 400
| Vol. | Page | Line | Error | Correction |
|---|---|---|---|---|
| 48 | 1911 | Summary Line 9 | reducing the residual rates of tacrolimus and everolimus by 8 and 17%, respectively, in vitro. | reducing the residual rates of tacrolimus and everolimus to 17 and 21% of the control, respectively, in vitro. |
| 1915 | Left 3 | reduced by 17 and 21%, | reduced to 17 and 21% of the control, | |
| Left 20 | reduced by 7, 5, and 10%, | reduced to 7, 5, and 10% of control, | ||
| Left 21 | reduced by 10, 9, and 30%. | reduced to 10, 9, and 30% of control. | ||
| 1916 | Left 4 | reduced tacrolimus residuals by 34–47%, | reduced tacrolimus residuals to 34–47%, | |
| Left 5 | reduced them by 37–52%. | reduced them to 37–52%. |